14h
Zacks Investment Research on MSNHow to Play VKTX Stock Amid Manufacturing Deal With CordenPharmaShares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...
7h
Zacks Investment Research on MSNViking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to NoteViking Therapeutics, Inc. (VKTX) closed at $29.73 in the latest trading session, marking a +0.61% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.91% for the day.
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...
1d
Zacks.com on MSNVKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug SupplyThe deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its ...
1don MSN
Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...
Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...
Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...
After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results